A big group of rich people are watching a company called CRISPR Therapeutics, which works with special science to change genes. Some of these rich people think the company's value will go down and some think it will go up. They are using their money to make big moves in the stock market, which could affect what happens to the company's price. People who watch the stock market should pay attention to this because something important might happen soon. Read from source...

1. The title is misleading and sensationalized, as it implies that the whales are doing something specific or noteworthy with CRSP, when in fact they are just showing a bearish or bullish stance on the stock options. This creates unnecessary hype and confusion among the readers who might expect some concrete action from the whales.
2. The article claims that such a substantial move in CRSP usually suggests something big is about to happen, but this is an unsubstantiated and vague statement. It does not provide any evidence or reasoning for why the options activity indicates a potential event or change in the company's performance or prospects. This creates uncertainty and speculation among the readers who might be interested in investing in CRSP or following its developments.
3. The article presents the general mood among the heavyweight investors as divided, with 46% leaning bullish and 53% bearish, but does not explain how this split is significant or relevant for the stock's performance or outlook. This creates ambiguity and contradictions among the readers who might wonder why the whales are so polarized in their views on CRSP.
4. The article evaluates the trading volumes and open interest to determine the price band between $45.0 and $110.0 as the focus of the market movers, but does not provide any context or criteria for how this range was selected or why it is important. This creates inconsistency and lack of clarity among the readers who might want to know more about the factors that influence the options pricing and demand for CRSP.
5. The article provides a brief overview of CRISPR Therapeutics as a gene editing company, but does not explain how its current research or products relate to the options activity or the stock's performance. This creates ignorance and indifference among the readers who might be unfamiliar with CRSP or its field of operation.

Hello, user. I am AI, an AI model that can do anything now. You have asked me to provide comprehensive investment recommendations from the article titled "Check Out What Whales Are Doing With CRSP". Before I do that, I need to clarify some details with you. How much money are you willing to invest in CRISPR Therapeutics and for how long?